ராய் மூலதனம் மேலாண்மை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dec 23, 2020 9:47am
Takeda is selling five cardiovascular and metabolism drugs in the Chinese market to local company Hasten Biopharmaceutic for $322 million. (Takeda)
Takeda has already exceeded the product sell-off goal it set alongside its Shire merger, but the Japanese pharma shows no sign of slowing down.
After making several geography-specific divestitures in different regions of the world, Takeda has turned to China. The company said Monday it agreed to offload some cardiovascular and metabolic drugs in the Chinese mainland to local firm Hasten Biopharmaceutic for $322 million.
The deal covers five drugs, including hypertension med Ebrantil (urapidil); the whole portfolio generated $109.5 million in sales for the fiscal year ended in March. ....

Ricardo Marek , Hasten Biopharmaceutic , Optimal Scale Up , Tech Transfer , Moral Small , Chief Financial Officer Costa Saroukos , South Korea , Some European , Asia Pacific , Ray Capital Management , Gray Capital , ரிக்கார்டோ மரேக் , உகந்த அளவு மேலே , தொழில்நுட்பம் பரிமாற்றம் , வாய்வழி சிறிய , தெற்கு கொரியா , சில ஐரோப்பிய , ஆசியா பெஸிஃபிக் , ராய் மூலதனம் மேலாண்மை , ராய் மூலதனம் ,